HUP0300917A2 - Bradikardiakumok alkalmazása hipertrófiával társult miokardiális betegségek kezelésére és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Bradikardiakumok alkalmazása hipertrófiával társult miokardiális betegségek kezelésére és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0300917A2
HUP0300917A2 HU0300917A HUP0300917A HUP0300917A2 HU P0300917 A2 HUP0300917 A2 HU P0300917A2 HU 0300917 A HU0300917 A HU 0300917A HU P0300917 A HUP0300917 A HU P0300917A HU P0300917 A2 HUP0300917 A2 HU P0300917A2
Authority
HU
Hungary
Prior art keywords
hypertrophy
treatment
diseases associated
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU0300917A
Other languages
English (en)
Inventor
Jürgen Dämmgen
Brian Guth
Randolph Seidler
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co. Kg
Publication of HUP0300917A2 publication Critical patent/HUP0300917A2/hu
Publication of HUP0300917A3 publication Critical patent/HUP0300917A3/hu
Publication of HU228387B1 publication Critical patent/HU228387B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A találmány tárgya bradikard anyagok, így Ca++-csatorna-blokkolók b-receptor-blokkolók és if-csatorna-blokkolók, elsősorbancsatornablokkolók új alkalmazása hipertrófiával társultszívizombetegségek kezelésére. A bradikard anyagokat a találmányszerint előnyösen egy szívre ható vegyülettel együtt alkalmazzák,amely vegyület egy szívglikozid, értágító, ACE-inhibitor vagyangiotenzin-II antagonista. A találmány szerintigyógyszerkészítményekkel elsősorban ideopátiás hipertrófiásszívizombetegségek kezelhetők, emberekben és háziállatokban. Ó
HU0300917A 2000-04-13 2001-04-07 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and pharmaceutical compositions containing them HU228387B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10018401A DE10018401A1 (de) 2000-04-13 2000-04-13 Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
PCT/EP2001/004034 WO2001078699A2 (de) 2000-04-13 2001-04-07 Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen

Publications (3)

Publication Number Publication Date
HUP0300917A2 true HUP0300917A2 (hu) 2003-08-28
HUP0300917A3 HUP0300917A3 (en) 2009-04-28
HU228387B1 HU228387B1 (en) 2013-03-28

Family

ID=7638652

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300917A HU228387B1 (en) 2000-04-13 2001-04-07 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and pharmaceutical compositions containing them

Country Status (33)

Country Link
US (2) US7208508B2 (hu)
EP (2) EP1276476B1 (hu)
JP (1) JP3905386B2 (hu)
KR (1) KR20020089453A (hu)
CN (1) CN1245963C (hu)
AT (1) ATE330588T1 (hu)
AU (2) AU2001270484B2 (hu)
BG (1) BG65816B1 (hu)
BR (1) BR0109996A (hu)
CA (2) CA2575059A1 (hu)
CY (1) CY1105081T1 (hu)
CZ (1) CZ300549B6 (hu)
DE (2) DE10018401A1 (hu)
DK (1) DK1276476T3 (hu)
EA (1) EA006977B1 (hu)
EE (1) EE05099B1 (hu)
ES (1) ES2266216T3 (hu)
HR (1) HRP20020815A2 (hu)
HU (1) HU228387B1 (hu)
IL (2) IL152103A0 (hu)
ME (1) MEP45908A (hu)
MX (1) MXPA02009935A (hu)
NO (1) NO330311B1 (hu)
NZ (1) NZ521934A (hu)
PL (1) PL215235B1 (hu)
PT (1) PT1276476E (hu)
RS (1) RS51478B (hu)
SI (1) SI1276476T1 (hu)
SK (1) SK286075B6 (hu)
TR (1) TR200202326T2 (hu)
UA (1) UA78679C2 (hu)
WO (1) WO2001078699A2 (hu)
ZA (1) ZA200208162B (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10018401A1 (de) 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
US20040138306A1 (en) 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
DE60200160T2 (de) * 2002-07-25 2004-11-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Cilobradine oder pharmazeutisch akzeptablen Salze zur Behandlung oder Prävention von Herzversagen
KR101194453B1 (ko) * 2003-01-31 2012-10-24 다이이찌 산쿄 가부시키가이샤 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
CN101247832B (zh) * 2005-06-27 2011-12-28 第一三共株式会社 含有血管紧张素ⅱ受体拮抗剂和钙通道阻断剂的药物制剂
WO2007023775A1 (ja) * 2005-08-23 2007-03-01 Astellas Pharma Inc. 心房細動治療剤
EP1762179A1 (en) 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
EP1908469A1 (en) * 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP2432452B1 (de) 2009-05-20 2016-07-27 Boehringer Ingelheim Vetmedica GmbH Pharmazeutische telmisartan-trinklösung
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
KR101296743B1 (ko) * 2011-02-17 2013-08-20 한국과학기술연구원 심근 비대증 진단용 바이오마커 및 이를 이용한 심근 비대증 진단 방법
JP2014521714A (ja) 2011-08-12 2014-08-28 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング ネコ科動物の心不全を治療および予防する方法において使用するための奇異性電流（Ｉｆ）阻害薬
WO2014122248A1 (en) 2013-02-11 2014-08-14 Boehringer Ingelheim Vetmedica Gmbh Kit-of-parts
JP7050893B2 (ja) 2017-07-07 2022-04-08 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ネコの全身性疾患の予防又は治療用アンジオテンシンｉｉ受容体拮抗薬
KR102398532B1 (ko) 2020-07-20 2022-05-13 한림대학교 산학협력단 중증 지주막하출혈 진단용 조성물
KR102331806B1 (ko) 2020-07-20 2021-12-01 한림대학교 산학협력단 중증 지주막하출혈 진단용 바이오 마커

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759125A (fr) 1969-11-19 1971-05-18 Boehringer Sohn Ingelheim Nouvelles n-allyl-2-arylamino-imidazolines-(2) substituees et procedes pour les fabriquer
DE3119874A1 (de) 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
DE3541811A1 (de) * 1985-11-27 1987-06-04 Thomae Gmbh Dr K Neue cyclische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3736866A1 (de) * 1987-10-30 1989-05-11 Thomae Gmbh Dr K Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz
DE3805635A1 (de) 1988-02-24 1989-09-07 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
RU2078536C1 (ru) * 1993-09-02 1997-05-10 Украинский научно-исследовательский институт кардиологии им.акад.Н.Д.Стражеско Способ определения клинической эффективности применения верапамила и дилтиазема у больных гипертрофической кардиомиопатией
CN1135757A (zh) * 1993-09-24 1996-11-13 普罗克特和甘保尔公司 新型含脱氧和氧被取代的糖的14-氨基类固醇
US5595987A (en) * 1994-07-22 1997-01-21 The Trustees Of Columbia University In The City Of New York Method of slowing ventricular arrhythmias using zatebradine
US6083991A (en) * 1997-06-04 2000-07-04 University Of Florida Research Foundation, Inc. Anti-arrhythmic composition and methods of treatment
DE19741635A1 (de) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
SG142116A1 (en) * 1998-07-10 2008-05-28 Novartis Ag Antihypersensitive combination of valsartan and calcium channel blocker
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
US20040138306A1 (en) * 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
CA2435526A1 (en) 2002-07-25 2004-01-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of cyclic amine derivatives or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
EP1762179A1 (en) * 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography

Also Published As

Publication number Publication date
TR200202326T2 (tr) 2003-03-21
KR20020089453A (ko) 2002-11-29
AU2001270484B2 (en) 2007-01-25
DE50110262D1 (de) 2006-08-03
US20070155679A1 (en) 2007-07-05
DE10018401A1 (de) 2001-10-25
EA006977B1 (ru) 2006-06-30
ATE330588T1 (de) 2006-07-15
CZ20023752A3 (cs) 2003-03-12
NO330311B1 (no) 2011-03-28
CA2575059A1 (en) 2001-10-25
PT1276476E (pt) 2006-09-29
MEP45908A (en) 2011-02-10
CA2404120C (en) 2008-01-22
SI1276476T1 (sl) 2006-10-31
BG107103A (bg) 2003-04-30
CZ300549B6 (cs) 2009-06-10
ES2266216T3 (es) 2007-03-01
RS51478B (sr) 2011-04-30
CN1422153A (zh) 2003-06-04
CN1245963C (zh) 2006-03-22
IL152103A (en) 2008-07-08
WO2001078699A2 (de) 2001-10-25
BR0109996A (pt) 2003-05-27
SK286075B6 (sk) 2008-03-05
HU228387B1 (en) 2013-03-28
EE200200590A (et) 2004-04-15
YU76902A (sh) 2006-05-25
NO20024924D0 (no) 2002-10-11
UA78679C2 (en) 2007-04-25
WO2001078699A3 (de) 2002-06-20
EP1276476B1 (de) 2006-06-21
EA200201053A1 (ru) 2003-02-27
EP1276476A2 (de) 2003-01-22
PL357827A1 (en) 2004-07-26
US7208508B2 (en) 2007-04-24
EP1666042A3 (de) 2006-06-21
ZA200208162B (en) 2003-10-17
PL215235B1 (pl) 2013-11-29
MXPA02009935A (es) 2003-02-12
AU7048401A (en) 2001-10-30
HRP20020815A2 (en) 2004-12-31
NO20024924L (no) 2002-10-11
HUP0300917A3 (en) 2009-04-28
DK1276476T3 (da) 2006-08-14
IL152103A0 (en) 2003-07-31
CY1105081T1 (el) 2009-11-04
US20040014795A1 (en) 2004-01-22
SK14582002A3 (sk) 2003-03-04
EE05099B1 (et) 2008-12-15
CA2404120A1 (en) 2001-10-25
JP3905386B2 (ja) 2007-04-18
BG65816B1 (bg) 2010-01-29
NZ521934A (en) 2007-05-31
EP1666042A2 (de) 2006-06-07
JP2003535050A (ja) 2003-11-25

Similar Documents

Publication Publication Date Title
HUP0300917A2 (hu) Bradikardiakumok alkalmazása hipertrófiával társult miokardiális betegségek kezelésére és ezeket tartalmazó gyógyszerkészítmények
GT199700074A (es) Derivados de 2-(2-oxo-etiliden)-imidazolidin-4-ona
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
TR200103186T2 (tr) MEK enzimlerinin inhibitörleri olarak kinolin türevleri
HUP0301842A2 (hu) Laktám vegyület, a vegyületet tartalmazó gyógyszerkészítmény és alkalmazása gyógyszerkészítmény elżállítására
EA200201271A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
EP1673078A4 (en) BENZYL ETHER AND BENZYLAMINO BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
EE200100485A (et) Uudsed ühendid ja kompositsioonid proteaasi inhibiitoritena
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
AR023130A1 (es) Composiciones para promover el crecimiento
HUP0301452A2 (hu) Fotokemoterápiás szert és mukoadhéziós szert tartalmazó gyógyszerkészítmény és alkalmazása
DK0910647T3 (da) Human DNase i hyperaktive varianter
EE200300475A (et) Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
EE201100023A (et) Ravimite kombinatsioon, mis sisaldab rasvhapet ja uridiin hendit, ja selle kasutamine
SE9900961D0 (sv) Novel compounds
DE60033649D1 (de) Verbindungen und therapeutische methoden
BR0313239A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de doenças
DE50012571D1 (de) Biotin enthaltende galenische formulierung
HUP0400553A2 (hu) Gyógyászati készítmények
DK1303278T3 (da) Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme
DK1608655T3 (da) Pyrroloimidazolderivater, fremstillingen deraf, farmaceutiske præparater indeholdende disse og anvendelse deraf som nootrope midler

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees